Rosy results of ABRAXANE benefit of bladder cancer prop up efficacy of nab-driven chemotherapy
Abraxis BioScience, Inc. (NASDAQ:ABII) announced today that findings from a facet 1 randomized judicial proceeding demonstrated that the nanoparticle albumin destined (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® concerning Injectable Deprivation; paclitaxel albumin protein-bound particles respecting injectable deferment is well-tolerated and physical in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to footing intra-bladder infusion (intravesical) group therapy. The results from a dispense escalation check of infusion of ABRAXANE presently into the bladder in these patients who bear failed ideal chemotherapy are being presented allowing for regarding the key in good time as a late-breaker during an articulated period on June 1st at the 2010 American Urological Linking Annual Congress in San Francisco.
“The heartening results of ABRAXANE in the treatment of patients with bladder cancer guy the efficacy of nab-driven chemotherapy across an increasing go of advanced and difficult-to-treat cancers”
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
